Medscape July 18, 2024
ORLANDO, Fla — Experts debating the pressing issue of how to prioritize patients in the increasingly common scenario of loss of access or insurance coverage for anti-obesity glucagon-like peptide 1 (GLP-1) receptor agonist drugs argued that comorbidities and obesity severity should strongly warrant continued coverage — while offering key strategies for getting and retaining approval from payers.
Paradoxically, “the demand for these drugs is growing just as the access and the coverage is going down,” emphasized Deborah Horn, DO, MPH, an associate professor and medical director at the University of Texas Health Science Center at Houston, who was among speakers in the lively session at the recent American Diabetes Association (ADA) 84th Scientific Sessions.
Underscoring the problem, Horn described a...
Today's Sponsors
Today's Sponsor